Viscosupplementation Market (By Application: Single Injection, Three Injection, Five Injection) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

Viscosupplementation is a treatment that aids in diminishing joint agony and improves the practical state of the osteoarthritic joint. It includes the infusion of a thick liquid called hyaluronate into the knee. Hyaluronic corrosive is found in the gooey synovial liquid that greased up the ligament surfaces and shields the joint from stun. This corrosive is a versatile substance that is normally emitted by mesothelial cells. Osteoarthritis—the most well-known kind of joint pain-is described by the loss of capacity and degeneration of ligament and tissues that spread the finishes of the bones in a joint. The rising worldwide pervasiveness of osteoarthritis prompts intense demand for osteoarthritis helpful items, including Viscosupplementation. As indicated by places for sickness control and counteractive action, more than 30 mn individuals in the US experienced osteoarthritis and around 10% of individuals more than 55 years experienced knee torment in later past.

As indicated by the national community for biotechnology data, 10% men and 13% ladies matured 60 years and more seasoned are experiencing osteoarthritis in the US. The commonness of osteoarthritis is high in females when contrasted with men, because of menopause and hormonal lopsidedness. A few factors that may prompt osteoarthritis are knee damage, stoutness, overweight, muscle shortcoming, loss of bone thickness, and the strain on joints, joint laxity, and so forth. Subsequently, the developing commonness of this malady is the main consideration adding to the development of the general viscosupplementation market.

The global viscosupplementation market size is estimated to reach 7.39 billion by the end of year 2026. The market is expected to grow at a CAGR of 9.4% over the forecast period 2019 to 2026.

Market Dynamics:

The expanding geriatric populace, rising predominance of osteoarthritis and way of life instigated issue, for example, heftiness, are a few elements expected to drive the development. As indicated by the Caspian Journal of Internal Medicine, around 13% of ladies and 10% of men experience the ill effects of osteoarthritis.

Great repayment situation is expected to make treatment for osteoarthritis progressively reasonable sooner rather than later. Medicare repays 80% of the patient permissible expense and the staying 20% rely upon patients' auxiliary safety net provider. France has a well-characterized repayment approach, along these lines, the nation holds a high offer in Europe. There are 13 viscosupplementations accessible in the nation, out of which 12 are repaid up to 65% by Social Security, for the treatment of knee osteoarthritis. As indicated by the International Society of Arthroscopy, Knee Surgery, and Orthopedic Sports Medicine (ISAKOS) in France, the items are repaid half of their value, which was endorsed in 2001.

The nearness of a solid item pipeline portfolio gives a chance to market development over the conjecture time frame. Carbylan started second Phase 3 out of 2016 concentrated on osteoarthritis treatment with and without Hydros-TA. Stage 2 gave positive outcomes in this manner boosting Phase 3 preliminaries.

According to the Osteoarthritis Research Society International (OARSI) U.S., the two corticosteroids and hyaluronic corrosive infusions can be utilized for the treatment of osteoarthritis, however, the impact of viscosupplementation is somewhat higher than that of corticosteroids. The administrative hindrances are moderately low in nations, for example, South Korea, which makes it an alluring marketplace for the business players to set their impression. Viscosupplementation is named specific medicine in South Korea.

Different components that are empowering the market development to incorporate developing games related wounds, reception of non-intrusive strategies and expanding demand for knee osteoarthritis. Also, improving human services framework and developing mindfulness about viscosupplementation is expected to offer a surprising open door for the development of the worldwide viscosupplementation market. In any case, there are sure factors confining the market development including stringent guidelines and antagonistic impacts related to viscosupplementation.

Market Insights:

In light of the item, the viscosupplementation market is segmented into the single infusion, three infusions, and five infusions. Because of the developing demand for shorter routine, single-infusion cycles are expected to enlist the quickest CAGR over the estimated time frame.

The three-infusion methodology segment is driving the market inferable from the lower cost of these items contrasted with single-infusion system items, and the shorter treatment routine in contrast with five-infusion technique items. Then again, single-infusion strategy holds the second biggest market pursued by the five-infusion technique for the viscosupplements market attributable to the propelled use in osteoarthritis and the utilization of single-infusion methodology requires fewer clinic visits and treats knee osteoarthritis for a half year.

MONOVISC from Anika Therapeutics is a solitary infusion hyaluronic corrosive that got the U.S. Sustenance and Drug Administration (FDA) endorsement in mid-2014. Another single-infusion item CINGAL, from a similar organization, is in the pipeline. Gel-One by Zimmer Holdings and Synvisc-One by Sanofi, are other advantageous single infusions accessible in the market.

The developing maturing populace is the key driver of the worldwide viscosupplementation market development. As indicated by the national foundation of wellbeing, there are around 617 million individuals of age 65 or more overall which is 8.5% of the all-out populace comprehensively. The developing maturing populace is very influenced by a wide scope of interminable illnesses, for example, osteoarthritis, malignancy, kidney, and a lot more infections. In this manner expanding maturing populace is the key driver of the worldwide viscosupplementation market development. Expanding demand for the insignificantly intrusive careful procedure and high patients’ mindfulness about the medication and gadgets for the treatment are energizing the viscosupplementation market. In addition, expanding fat populace are likewise developing the viscosupplementation market. Be that as it may, reactions, for example, infusion side agony and joint torment swelling are limiting variables of the worldwide viscosupplementation market.

Regional Insights:

North America market is the biggest viscosupplementation market comprehensively representing high item demand, high mindfulness in the region and acknowledgment of extravagant items. Europe market encountered a monetary downturn that made an issue in the hyaluronic corrosive items market as repayment strategies ended up being troublesome yet at the same time, the premium valued items were acknowledged in a portion of the nations. Despite the fact that the European market is expected to audit and give a basic chance to viscosupplementation items as the financial conditions are restoring. Asia-Pacific viscosupplementation market is particularly determined by financial improvement, social insurance office upgrades and extreme demand for insignificantly intrusive medical procedures.

The improvement of social insurance offices because of financial advancement in the developing nations, for example, China, Japan, South Korea, and India, have anticipated the Asia Pacific as the conceivably rewarding market. High mindfulness levels about single-infusion treatment and more noteworthy inclination for insignificantly obtrusive administration of osteoarthritis are expected to drive regional development.

Europe market is foreseen to watch the quickest development in the pending years. While adequacy and security are evaluated in different pieces of the world, Europeans see repayment and valuing as the definitive elements while picking the hyaluronic corrosive treatment. The general pattern winning among specialists is to maintain a strategic distance from knee substitution medical procedures beyond what many would consider possible, which has supported demand for torment the board through viscosupplementation.

Market Segmentation:

Market Segmentation By Application:

• Single Injection
• Three Injection
• Five Injection

Market Segmentation By Region:

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • Rest of MEA

Market Participants:

There is an enduring development in the market with the passage of new players. Different makers working in the market are presenting new items. For example, HAppyCross, HAppyVisc, and HAppyMini are a couple of items by Labrha, a France-based organization. In addition, HAppySoft (nonexclusive item) and HAppyOne (single intra-articular infusion) are in the pipeline.

While there are new participants, the current players are reinforcing their dependable balance by presenting as good as ever items. In March 2019, in Italy, Seikagaku Corporation propelled another intra-articular single-infusion viscosupplement named HyLink for the treatment of knee osteoarthritis.

In June 2016, Anika Therapeutics, Inc. propelled CINGAL in Europe. The organization expected to make the item accessible in Germany, Poland, Italy, Czech Republic, and Hungary. The item has gotten CE mark in March 2016. It denotes a significant activity in the organization's worldwide development. The organization displayed adequacy information for CINGAL in the 2017 European Federation of National Associations of Orthopedics and Traumatology Annual Congress, in May 2017. The organization is taking a shot at getting FDA endorsement to dispatch its item in the US.

Major companies contributing the global Viscosupplementation market are Anika Therapeutics, Inc., Bioventus, Contipro Biotech, Expanscience Laboratories, Ferring B.V., HTL Biotechnology, Hyaltech, LG Life Sciences Ltd., Lifecore Biomedical, LLC, Mylan, Sanofi, Seikagaku Corporation, and Zimmer Holdings Inc.